Advances in Clinical Immunology

Swati Dhar
Parexel International LLC, Chicago, USA
Correspondence to: dharswat@gmail.com

DOI: https://doi.org/10.70389/PJI.100004

Additional information

• Ethical approval: N/a
• Consent: N/a
• Funding: No industry funding
• Conflicts of interest: N/a
• Author contribution: Swati Dhar – Conceptualization, Writing – original draft, review and editing
• Guarantor: Swati Dhar
• Provenance and peer-review:
  Commissioned and externally peer-reviewed
• Data availability statement: N/a

Keywords: Bispecific antibodies, CAR T-cell therapy, Immune checkpoint inhibitors, Single-cell RNA sequencing, Artificial intelligence in immunology.

Peer-review
Received: 25 November 2024
Revised: 5 January 2025
Accepted: 6 January 2025
Published: 27 January 2025

Concepts in Clinical Immunology and Diseases

Clinical immunology focuses on studying the immune system in order to identify and treat illnesses linked to the immune system. It addresses disorders brought on by aberrant immune responses, whether they are poorly controlled, excessively active, or underactive (Figure 1). To treat illnesses caused by immune system dysfunction, clinical immunology integrates research, laboratory testing, and clinical practice.^1–5

The following are important areas of clinical immunology focus:

Autoimmune Diseases: These happen when the body’s own tissues are mistakenly attacked by the immune system. Multiple sclerosis, lupus, and rheumatoid arthritis (RA) are a few examples.

Immunodeficiency Disorders: They occur due to an immune-suppressed condition and make people more prone to infections. They can be classified as secondary (acquired, such as HIV/AIDS) or primary (genetic, such as severe combined immunodeficiency (SCID)).

Hypersensitivity Reactions: This group includes allergic reactions, in which the body’s defenses overreact to innocuous things (e.g., meals, pollen). This category includes diseases such as anaphylaxis, allergic rhinitis, and asthma.

Immune-Related Malignancies: Because certain malignancies, such as leukemia and lymphoma, start in immune system cells, immunologists should be interested in studying them.

The study of immunological reactions in organ or tissue transplantation, specifically the control of graft rejection and tolerance, is known as transplant immunology. Immunology plays a key role in the development of immune-modulating treatments such as monoclonal antibodies, CAR T-cell therapies, and vaccinations. Over the next 10 years, the clinical immunology market is expected to increase rapidly. The global immunology market is projected to grow from $98 billion in 2023 to over $263 billion by 2033. As autoimmune diseases such as multiple sclerosis (MS), RA, and Crohn’s disease become more common, as well as chronic illnesses that need immunological therapies, this market is expected to expand at a compound annual growth rate of about 10.4% through 2033.⁶

Key disease categories within clinical immunology are expanding due to several variables. The rise in cancer cases has increased demand for immunology-based treatments, especially in immuno-oncology, in addition to the growing number of patients with autoimmune and infectious diseases. Because of their success in boosting immune responses to target cancer cells, cancer medicines like checkpoint inhibitors and CAR T-cell therapy are becoming commonplace. Immunosuppressive medications are essential in the treatment of chronic inflammatory illnesses and transplant-related immunological disorders, two more fields that are gaining from advances in immunology. Innovations in technology are essential to the market’s growth. Among the main platforms promoting growth are:

Monoclonal Antibodies, or mAbs: They are widely utilized in the treatment of infectious, autoimmune, and cancerous disorders. They offer tailored therapies that improve the immune system’s capacity to combat particular disease signs. Treatment methods for diseases including RA and some types of cancer have changed as a result of this technology.

CAR T-Cell Therapy: This promising oncology treatment alters T-cells to target particular cancer cells. Research and acceptance have accelerated because of its potential for long-lasting remission in certain malignancies.

Scalability Issues and Ethical Issues with CAR T-Cell and CRISPR Technologies

Issues with Scalability

CAR T-Cell Therapy: The difficulty of producing customized treatments is one of the main obstacles to the expansion of CAR T-cell therapy. Before being reinfused, each patient’s T-cells need to be extracted, genetically altered, and grown in vitro. This customized technique is expensive, time-consuming, and resource-intensive. Furthermore, accessibility is restricted by the need for specialized facilities and knowledge, especially in environments with limited resources. Although the efforts to create “off-the-shelf” allogeneic CAR T-cell therapies hold immense potential, they are fraught with difficulties, such as the possibility of immunological rejection and graft-versus-host disease.

Ethical Concerns

CAR T-Cell Therapy: Access and equity are the main ethical issues in CAR T-cell therapy. Concerns regarding affordability and the possibility of escalating healthcare disparities are raised by the high expense of therapy, which frequently exceeds hundreds of thousands of dollars per patient. Furthermore, it is yet unclear how CAR T-cell therapy will affect patients in the long run, especially with regard to durability and unanticipated side effects, which calls for strict post-market monitoring.

CRISPR Technology: When used for germline editing, CRISPR presents significant ethical issues. Although most people agree that somatic editing can be used for therapeutic purposes, the potential for heritable changes raises questions about eugenics, unforeseen repercussions, and social injustice. The ethical ramifications of “editing out” particular characteristics or conditions, which can stigmatize those who have them, are also up for debate.

Key Diseases in Clinical Immunology, Challenges in Diagnosis, and Technological Platforms

An Overview of RA and Its Immunological Mechanism

The immune system targets synovial joints in RA, an inflammatory condition that causes persistent inflammation and joint destruction. T-cells and B-cells, as well as autoantibodies such as rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPAs), are among the various immunological pathways that are involved.^7,8

Difficulties in Detection and Identification

Because RA overlaps symptoms with other types of arthritis and inflammatory disorders, early identification is crucial yet difficult. Although RF and ACPAs are biomarkers, they are not unique to RA, which could result in false-positive results. Although they can identify joint inflammation, imaging techniques like MRI and ultrasound may be restricted in their availability and affordability.

Commercial Advancements in Treatments

The main therapies are biologic therapeutics that target particular immune components and ­disease-
modifying antirheumatic medications. Commercially available but expensive biologics include Janus kinase inhibitors and TNF inhibitors (e.g., etanercept, adalimumab). In order to provide focused immune modulation at possibly cheaper costs and with fewer side effects, newer medicines are investigating small-molecule inhibitors.

Utilized Technologies

Proteomics and genomics-based biomarker analysis and advanced imaging are enhancing early diagnosis and treatment personalization. Prediction tools based on artificial intelligence (AI) and machine learning are also being investigated to assist in forecasting how an illness will advance and how well a treatment will work.

Overview of Systemic Lupus Erythematosus (SLE) and Mechanism of Immunology

Antibodies in SLE, a complicated autoimmune illness, target several organs, especially the joints, kidneys, and skin. Autoantibodies, such as antinuclear antibodies (ANA) and hyperactive B-cells, are components of immunological dysfunction.

Difficulties with Detection and Diagnosis

Clinical symptoms and test results, such as ANA and anti-dsDNA antibodies, are used to make the diagnosis. The diagnosis is made more difficult by the fact that these indicators are vague and can be present in both healthy people and those with autoimmune disorders.

Commercial Advancements in Therapeutics

Corticosteroids and immunosuppressants are examples of traditional medicines that have negative effects with extended use. Targeted therapy has become more popular with the development of biologics like belimumab, a B-cell inhibitor. The development of small-molecule inhibitors and safer biologics is of great commercial importance.

Technologies in Use

Innovative biomarker panels, flow cytometry, and gene expression profiling are being researched to increase diagnostic precision. In an effort to treat or lessen autoimmune reactions, CRISPR-based technologies are also being investigated for precision editing in immune cells.^9,10

Diseases of Primary Immunodeficiency (PIDs) Summary and Immunological Process

PIDs are hereditary conditions in which immune system components are absent or malfunctioning, making the body more vulnerable to infections. Common variable immunodeficiency and SCID are two examples.^11,12

Difficulties in Detection and Diagnosis

Because PID symptoms can vary and overlap with those of other immune-related illnesses, diagnosing PIDs can be difficult. Some PIDs can be detected early through newborn screening, but many are not recognized until later since they do not exhibit any particular symptoms. Although genetic testing is useful, it can be expensive and does not always identify all mutations.

Commercial Advancements in Treatments

Immunoglobulin replacement therapy and, in extreme situations, hematopoietic stem cell transplantation are among the available treatments. Recent advancements in gene therapy, particularly for SCID, aim to directly fix genetic abnormalities, making it a promising commercial field.

Technologies in Use

The diagnosis and categorization of PIDs depend heavily on next-generation sequencing and other genetic technologies. Immune function is also frequently evaluated quantitatively using ELISA-based immune function tests and flow cytometry.

Overview and Immunological Mechanism of Multiple Sclerosis

Neurological symptoms result from immune cells attacking the myelin sheath of neurons in MS, an autoimmune disease. T-cells and B-cells are involved in the illness, and cytokines like IL-17 play particular roles in the course of the illness.^13,14

Difficulties in Detection and Diagnosis

Since there are no reliable blood biomarkers for MS, diagnosis frequently entails MRI to find lesions, cerebrospinal fluid studies, and clinical evaluations. Delays in diagnosis may result from symptoms that resemble those of other neurological conditions.

Commercial Advancements in Treatments

Immunomodulatory medications such as interferons, monoclonal antibodies (like ocrelizumab), and small-molecule medications like fingolimod are examples of current treatments. Treatments that encourage remyelination and stop the course of the disease are the main focus of commercial research.

Technologies in Use

To enhance diagnosis and track therapy response, researchers are investigating AI-based imaging analysis, machine learning for diagnostic support, and liquid biopsy technologies.

Diabetes Mellitus Type 1 (T1DM) Summary and Immunological Process

Insulin insufficiency results from T lymphocytes attacking pancreatic beta cells in type 1 diabetes, an autoimmune illness. Environmental factors and genetic predisposition are both involved in the condition.^15,16

Problems with Detection and Diagnosis

Once significant beta-cell loss occurs, symptoms appear quickly, making early diagnosis difficult. Although autoantibody testing (such as for GAD65 or IA-2) is utilized for diagnosis, it has little predictive power in people who do not exhibit any symptoms.

Commercial Advancements in Treatments

Although immunomodulatory medications, beta-cell replacement, and gene therapy are being researched, insulin therapy is still the mainstay. In order to improve glucose management, T1DM research is also looking into artificial pancreas technology and closed-loop insulin delivery devices.

Technologies in Use

In the treatment of type 1 diabetes, continuous glucose monitoring and sophisticated insulin pumps are frequently utilized. Recent developments include gene-editing techniques to produce insulin-secreting cells or protect beta cells, as well as immune cell ­profiling.

Current Platforms Used in Clinical Immunology

A variety of cutting-edge technological platforms are used in clinical immunology to diagnose, track, and treat immune-related disorders. These systems aid in the detailed analysis of immune responses, offering insights that inform research and clinical interventions.^17,18

Mass Cytometry (CyTOF) and Flow Cytometry

The fundamental tools for immune monitoring are mass cytometry (CyTOF) and flow cytometry, which provide in-depth immune cell profiling. For high-dimensional cellular investigation, which is essential for describing intricate immune responses, CyTOF employs metal-tagged antibodies. Similar to flow cytometry, it facilitates multiparameter analysis and is frequently used in routine clinical settings to enhance transplant immunology research, identify immune cell subpopulations, and assess functional responses. The development of vaccines and gene therapy heavily relies on viral and non-viral vector technologies. Therapeutic genes are delivered to cells by viral vectors such as lentiviruses and adeno-associated viruses. With the creation of mRNA vaccines, non-viral techniques like lipid nanoparticles gained popularity. For example, lipid-based formulations of COVID-19 vaccines preserve mRNA and promote cellular penetration. Another exciting avenue in clinical immunology is RNA and DNA vaccines. In order to increase the cellular uptake of DNA plasmids, which subsequently express antigens and boost immunity, DNA vaccines rely on electroporation. Pandemic response can benefit from the ease and speed of production of RNA vaccines, particularly those encased in lipid nanoparticles. Because of its replicative qualities, self-amplifying RNA, a next-generation form, requires lower doses and provides a scalable approach for future immunotherapies.¹⁹

Technological Platforms and Novel Therapeutics Advancing the Field of Clinical Immunology

Antibody Engineering

To tackle the mutation issues of viruses such as SARS-CoV-2, Mount Sinai created the Adaptive Multi-Epitope Targeting and Avidity-Enhanced  Nanobody Platform, a novel antibody technique. By simultaneously targeting several stable viral areas, this platform lessens the virus’s capacity to mutate itself out of treatment. This multi-targeting approach has the potential to provide long-lasting defense against rapidly changing infections.²⁰

Multi-Omics Integration

To investigate immune responses in various diseases, the Center for Human Immunology, Inflammation, and Autoimmunity (CHI) at the National Institutes of Health (NIH) has led the way in multi-omics technology. It uses proteomics, single-cell genomics, and high-parameter cytometry. This thorough data integration promotes innovative treatment approaches by enabling a greater knowledge of immune system dysregulation in illnesses ranging from cancer to autoimmune diseases. By combining machine learning, powerful bioinformatics, and iterative learning, the AI-ImmunologyTM platform has greatly increased the accuracy of its vaccination target predictions. The phase 2 trial of the tailored cancer vaccine EVX-01 showed this improvement, with 79% of AI-predicted vaccine sites eliciting a tumor-specific immune response, up from 58% in the phase 1 study. When compared to conventional techniques, the platform’s increased accuracy in finding immune-responsive sites highlights its potential to improve the clinical efficacy and business prospects of AI-derived vaccines.²¹ A summary of current technologies and platforms used in clinical immunology is provided in Table 1.

Table 1: Current technological platforms in clinical immunology.
Technology	Principle	Applications	Advantages	Limitations
Enzyme-Linked Immunosorbent Assay (ELISA)	Antigen-antibody interaction; uses an enzyme for signal amplification.	Detection of specific antigens or antibodies (e.g., autoimmune disorders, allergies, infections).	High sensitivity, specificity, quantitative or qualitative analysis, cost-effective.	Limited multiplexing capability, time-consuming.
Flow Cytometry	Measures physical and chemical properties of cells in suspension via laser-based technology.	Immunophenotyping, diagnosis of leukemia/lymphoma, immune cell function analysis.	Multiparametric analysis, high throughput, real-time data.	Expensive, requires technical expertise, complex data analysis.
Immunofluorescence Microscopy (IFM)	Uses fluorescent-labeled antibodies to detect specific antigens in cells/tissues.	Autoimmune disease diagnostics (e.g., ANA, lupus), detection of infectious agents.	High specificity, can visualize cellular/tissue localization of antigens.	Requires expensive equipment, limited quantitative analysis, potential for subjectivity in interpretation.
Western Blotting	Separation of proteins via gel electrophoresis followed by antibody detection.	Confirmation of autoimmune and infectious disease diagnoses (e.g., Lyme disease, HIV).	High specificity, confirmatory testing.	Labor-intensive, semi-quantitative, low throughput.
Luminex Assay	Bead-based multiplex assay detecting multiple analytes in a single sample.	Cytokine profiling, autoimmune and allergy testing, HLA typing.	High throughput, multiplexing capability, cost-effective for large studies.	Requires specialized equipment, higher upfront cost.
PCR-Based Assays (e.g., qPCR, RT-PCR)	Amplifies specific DNA/RNA sequences for quantitative analysis.	Diagnosing viral infections, genetic mutations, assessing immune-related gene expression.	High sensitivity, specificity, quantitative output, rapid.	Requires advanced equipment and technical expertise, potential contamination risk.
Next-Generation Sequencing (NGS)	High-throughput sequencing of DNA/RNA.	Immunogenomics, immune repertoire sequencing, pathogen detection.	Comprehensive data, high sensitivity, customizable for diverse applications.	Expensive, requires bioinformatics expertise, large data storage.
Mass Spectrometry (e.g., MALDI-TOF)	Measures mass-to-charge ratio of molecules for protein/peptide identification.	Autoantibody identification, peptide/protein characterization, biomarker discovery.	Highly accurate, broad applications, high throughput.	High cost, requires expertise, not routine in many clinical settings.
Electrochemiluminescence (ECL)	Uses electrochemical stimulation to produce luminescence in the presence of target analytes.	Immunoassays for cytokines, biomarkers in autoimmune diseases and infections.	High sensitivity, broad dynamic range, suitable for low-abundance analytes.	Expensive equipment, limited widespread availability.
Immunohistochemistry (IHC)	Antibody-based detection of antigens in tissue sections using chromogenic/fluorescent labeling.	Cancer immunology, infectious disease pathology, autoimmune diseases.	High specificity, contextual information on antigen localization.	Labor-intensive, potential for subjectivity, limited multiplexing capability.
Complement Fixation Test (CFT)	Measures complement consumption during antigen-antibody reaction.	Diagnosis of certain infections (e.g., Q fever, fungal infections).	Simple, well-established.	Low sensitivity, qualitative or semi-quantitative, not widely used in modern laboratories.
Radioimmunoassay (RIA)	Uses radioactive isotopes to detect antigen-antibody complexes.	Hormone level measurement, autoimmune markers, allergy testing.	Highly sensitive, can detect low-abundance analytes.	Safety concerns with radioactive materials, requires specialized handling and disposal.
Cell Culture Assays	In vitro culture of immune cells to study their response to stimuli.	Functional immune studies, vaccine development, drug testing.	Provides functional insights, flexible setup.	Time-consuming, labor-intensive, requires sterile facilities.

Celldex Therapeutics: Using Innovative Antibodies to Treat Prolonged Hives

Although chronic hives may seem insignificant, they can be extremely painful and incapacitating for people with disorders like symptomatic dermographism (SD) or cold urticaria (ColdU). Many individuals lack access to effective therapy choices because traditional antihistamines do not always work. Celldex introduces barzolvolimab, a new anti-c-KIT antibody. Barzolvolimab showed remarkable success in lowering the symptoms of chronic hives in Celldex’s most recent phase 2 trials. Celldex is providing these patients with a real sense of relief, as almost half of the patients receive negative test results for ColdU and SD after just 12 weeks. Barzolvolimab is also being trialed in chronic spontaneous urticaria and a rare skin disorder called prurigo nodularis, showing its broad potential. As it gears up for a phase 3 trial, Celldex is well-positioned to revolutionize treatment options for patients who have long been underserved.²²

Rezolute: A Treatment for Congenital Hyperinsulinism That Can Save Lives

A potentially fatal disorder known as congenital hyperinsulinism (HI) mainly affects newborns and young children and results in dangerously low blood sugar levels. There have not been many therapy choices up to this point, and many kids have serious developmental delays or problems that could change their lives. However, Rezolute’s medication candidate, ersodetug, is altering that perception. Rezolute is now moving on with a crucial phase 3 trial in the US after overcoming regulatory obstacles, giving HI families fresh hope. In patients with hyperactive pancreas, this monoclonal antibody helps to normalize blood sugar levels by targeting insulin receptors.²³ The development of CAR T-cell treatments for autoimmune illnesses has advanced, thanks to Kyverna Therapeutics. Chimeric antigen receptor technology, which is used by Kyverna’s top candidate KYV-101, has the ability to specifically target and eliminate hyperactive immune cells while preserving healthy tissue. This strategy seeks to lessen dependency on conventional immunosuppressive therapies, which frequently have serious adverse effects.

Phase 1 and 2 clinical trials of KYV-101 are presently being conducted for systemic sclerosis and lupus nephritis, with further research focusing on autoimmune diseases such as MS and myasthenia gravis. By offering more accurate, long-lasting, and secure therapies for these difficult illnesses, the therapy may present a revolutionary substitute. Kyverna has drawn a lot of investment, including $145 million in Series B funding to support pipeline growth and continued clinical development.²⁴ Finding the proper medication promptly is typically critical for people with secondary hemophagocytic lymphohistiocytosis (sHLH), a potentially fatal hyperinflammatory disease. With its innovative monoclonal antibody treatment called ELA026, Electra Therapeutics is providing a ray of hope. ELA026 demonstrated a 100% response rate in patients with malignancy- associated HLH, the most severe type of sHLH, in a phase 1 trial. An important development for this fatal illness was the increase in survival rates brought about by early therapy. The medication gives a new lease on life to patients who had few other options by ­specifically targeting the immune cells that cause the harmful inflammation in sHLH.

Electra Therapeutics is poised to provide a much-needed treatment for this debilitating illness, thanks to its excellent safety profile and encouraging early results.²⁵ Chronic obstructive pulmonary disease (COPD) causes airflow obstructions and breathing difficulties, such as emphysema and chronic bronchitis. It is a leading cause of death worldwide, affecting around 391 million people. With substantial death rates—one in five patients die within a year after their first severe exacerbation—COPD raises the risk of cardiopulmonary events.

Extreme Asthma

It is a crippling illness that affects up to 26 million individuals worldwide. Despite taking large doses of common asthma drugs, patients frequently have uncontrolled symptoms, which impair their quality of life and cause recurrent exacerbations.

Eosinophilic Granulomatosis with Polyangiitis

Approximately 118,000 people worldwide suffer from this uncommon inflammatory illness. Small to medium-sized blood arteries become inflamed in eosinophilic granulomatosis with polyangiitis, which can harm the heart, lungs, and nerves, among other organs. Without efficient treatment, the disease can be fatal, and nearly half of patients fail to achieve remission.

Tezepelumab, or Tezspire

Tezspire, a monoclonal antibody created by AstraZeneca and Amgen, targets TSLP, a cytokine essential for causing and maintaining airway inflammation. Tezspire is a first-in-class therapeutic option that has been approved for the treatment of severe asthma in a number of countries, including the US, the EU, and Japan. Trixeo/Breztri Aerosphere: Formoterol fumarate (LABA), glycopyrronium bromide (LAMA), and budesonide (ICS) are present in this triple-combination inhaler. This has been approved for the treatment of COPD in more than 50 nations, including China, Japan, the US, and the EU.26 It is being assessed in phase 3 trials for asthma and is administered via a pressurized metered-dose inhaler (pMDI).²⁷

Benralizumab (Fasenra)

It is a monoclonal antibody that targets eosinophils’ IL-5 receptor alpha, causing apoptosis and subsequent eosinophil depletion. It is accessible for self-administration in many areas and has been approved in more than 80 nations for severe asthma. Prescribed to over 120,000 patients worldwide, it was developed by AstraZeneca in collaboration with BioWa, Inc.²⁸

Airsupra (albuterol/budesonide)

It is a first-in-class rescue treatment for asthma in the US, combining albuterol (SABA) and budesonide (ICS) in a fixed-dose inhaled medication. Designed for as-needed use, it utilizes AstraZeneca’s Aerosphere pMDI technology for effective delivery. The field of immunology in the pharmaceutical industry continues to grow, emphasizing its importance and continuous advancements. The long-running bestseller Humira from AbbVie is a prime example of the effectiveness of immune-targeted treatments for diseases like Crohn’s disease, psoriasis, ulcerative colitis, and arthritis. Companies like AbbVie and J&J are developing next-generation medications like Skyrizi, Rinvoq, and Tremfya in response to the growing competition from biosimilars.

A significant advancement with a focus on interleukin-23 (IL-23) inhibitors was initiated by researchers such as Daniel Cua of Janssen. After being eclipsed by IL-12 at first, IL-23 became a more accurate target for immune-inflammatory illnesses, resulting in less harmful treatments. The prospect of oral medicines and combination treatments, including IL-23 inhibitors with anti-TNF medications like Simponi that are presently undergoing clinical trials, is highlighted by Cua.²⁹ The sector’s attractiveness is reflected in M&A activity. Merck’s $10.8 billion acquisition of Prometheus Biosciences underscores the competition to develop innovative immunology therapies. Prometheus’s lead candidate known as PRA023 targets Crohn’s disease and ulcerative colitis, exemplifying the field’s rapid growth and appeal despite market saturation. Analysts predict significant advances within three to five years, driven by genetic insights and evolving mechanisms of action. Immunology’s relevance across diseases like cancer and infections ensures sustained innovation and investment in the field.

Prospects with Artificial Intelligence in the Realm of Clinical Immunology

How AI and machine learning could improve the diagnosis and treatment of inborn errors of immunity (IEIs) was the focus of the first Artificial Intelligence in Primary Immune Deficiencies conference.^30–32 Among the main subjects were:

Accelerating IEI Diagnoses: AI-based technologies have discovered novel warning patterns for IEIs utilizing claims data and electronic health records (EHRs), which have improved patient outcomes and diagnosis speed.

Difficulties in Gathering Data: Effective AI system training is hampered by rare diseases, overlapping phenotypes, and data biases.

Natural Language Processing (NLP) and Large Language Model (LLM) roles: LLMs and NLP are essential tools for deciphering unstructured data in EHRs.

Practical and Ethical Aspects to Consider: Data protection, fair access, regulatory issues, and the necessity of open science to alleviate inequalities and improve teamwork were highlighted in the conversations. The meeting concluded that while AI holds transformative potential for clinical immunology, integration into routine practice requires overcoming significant challenges and fostering collaboration.

Present Understanding and Future Directions of AI in Clinical Immunology

• Improvement of Diagnosis: By evaluating sizable datasets, finding trends, and combining various data types such as genomic, proteomic, and clinical records, AI tools have demonstrated promise in the early identification of immunological illnesses. These methods speed up the identification of complicated and uncommon diseases, especially those with mild phenotypes or overlapping symptoms.
• Tailored Care: By determining the best therapeutic targets and forecasting medication responses based on patient-specific variables, AI-driven insights from patient data allow for individualized treatment plans.
• EHR Utilization and NLP AI models, especially those that make use of NLP, make it easier to retrieve clinically significant data from unstructured EHRs. This improves the precision of monitoring the course of the disease and identifying symptoms that are essential for diagnosis.
• Analytics for Prediction: Clinicians can prioritize interventions for high-risk patients by using machine learning algorithms that can predict illness outcomes and risk stratification.
• Regulatory and Ethical Aspects: Adopting AI in clinical immunology necessitates overcoming algorithmic biases and adhering to data protection regulations to guarantee equitable treatment. In order to thoroughly assess and validate AI tools, regulatory frameworks must also change.

Conclusions

Over the past few decades, clinical immunology has advanced significantly due to a better understanding of immune system mechanisms and how they affect both health and illness. Modern diagnostic and treatment techniques are based on fundamental ideas including immunological tolerance, dysregulation, and the complex balance between pro-inflammatory and anti-inflammatory pathways. Monoclonal antibodies, checkpoint inhibitors, and customized vaccinations are examples of immunotherapies that have revolutionized the way that autoimmune illnesses, infectious diseases, and tumors are treated.

Our capacity to examine immune responses at previously-unheard-of resolution has been completely transformed by the incorporation of new technology platforms, including single-cell sequencing, high-dimensional flow cytometry, and sophisticated imaging methods. Precision medicine, the discovery of new biomarkers, and an understanding of disease heterogeneity have been made possible by these technologies. Additionally, computer modeling and omics technologies continue to uncover previously hidden patterns in immune function, further accelerating discovery. AI has the potential to revolutionize clinical immunology in the future. AI can improve diagnostic precision, optimize treatment plans, and more accurately forecast patient outcomes by utilizing machine learning algorithms and big data analytics. Additionally, by identifying promising therapeutic targets and customizing therapies for each patient, AI-powered platforms have the potential to expedite drug research and development. To guarantee the proper use of these game-changing capabilities, ethical issues, data protection, and the requirement for interdisciplinary cooperation continue to be crucial as we adopt these breakthroughs. In conclusion, a new age in clinical immunology is being ushered in by the combination of basic immunological research, advanced technology, and AI. This comprehensive strategy has the potential to enhance patient care, increase our knowledge of immune-related disorders, and propel the next wave of breakthroughs in human health.

References

1 Zabriskie JB, editor. Essential Clinical Immunology. 2009. Cambridge University Press.
https://doi.org/10.1017/CBO9780511575266
 
2 Tozzoli R, D’Aurizio F, Villalta D, Bizzaro N. Automation, consolidation, and integration in autoimmune diagnostics. Auto Immun Highlights. 2015;6(1-2):1-6.
https://doi.org/10.1007/s13317-015-0067-5
 
3 Ura T, Takeuchi M, Kawagoe T, Mizuki N, Okuda K, Shimada M. Current vaccine platforms in enhancing T-cell response. Vaccines (Basel). 2022;10(8):1367.
https://doi.org/10.3390/vaccines10081367
 
4 Lu B, Lim JM, Yu B, Song S, Neeli P, Sobhani N, et al. The next-generation DNA vaccine platforms and delivery systems: advances, challenges and prospects. Front Immunol. 2024;15:1332939.
https://doi.org/10.3389/fimmu.2024.1332939
 
5 Chinen J, Badran YR, Geha RS, Chou JS, Fried AJ. Advances in basic and clinical immunology in 2016. J Allergy Clin Immunol. 2017;140(4):959-73.
https://doi.org/10.1016/j.jaci.2017.07.023
 
6 Global Immunology Market Size, Share, Trends and Growth Forecast Report – Segmented By Drug Class, Disease Indication, Distribution Channel & Region – Industry Analysis from (2024 to 2029) 2024. Available from: https://www.marketdataforecast.com/market-reports/immunology-market.
 
7 Smolen JS Aletaha D McInnes IB. Rheumatoid arthritis. The Lancet. 2016;388(10055):2023-8.
https://doi.org/10.1016/S0140-6736(16)30173-8
 
8 Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320(13):1360-72.
https://doi.org/10.1001/jama.2018.13103
 
9 Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110-21.
https://doi.org/10.1056/NEJMra1100359
 
10 Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-45.
https://doi.org/10.1136/annrheumdis-2019-215089
 
11 Casanova JL, Abel L. Primary immunodeficiencies: a field in its infancy. Science. 2007;317(5838):617-9.
https://doi.org/10.1126/science.1142963
 
12 Notarangelo LD, Uzel G, Rao VK. Primary immunodeficiencies: novel genes and unusual presentations. Hematology Am Soc Hematol Educ Program. 2019;2019(1):443-8.
https://doi.org/10.1182/hematology.2019000051
 
13 Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, et al. Multiple sclerosis. Nat Rev Dis Primers. 2018;4(1):43.
https://doi.org/10.1038/s41572-018-0041-4
 
14 Hauser SL, Cree BAC. Treatment of multiple sclerosis: a review. Am J Med. 2020;133(12):1380-90 e2.
https://doi.org/10.1016/j.amjmed.2020.05.049
 
15 Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;383(9911):69-82.
https://doi.org/10.1016/S0140-6736(13)60591-7
 
16 Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010;464(7293):1293-300.
https://doi.org/10.1038/nature08933
 
17 Slieman TaL, J. Introduction to immunological techniques in the clinical laboratory. Methods Microbiol. 2020;47:1-16.
https://doi.org/10.1016/bs.mim.2020.01.001
 
18 NIH Center for Human Immunology, Inflammation, and Autoimmunity (CHI) https://www.niaid.nih.gov/research/nih-center-human-immunology-inflammation-and-autoimmunity-chi
 
19 Lopez-Camacho C, Alameh MG, Peer D, Culis P. Editorial: RNA vaccines for prevalent and newly emerging diseases. Front Immunol. 2024;15:1474260.
https://doi.org/10.3389/fimmu.2024.1474260
 
20 Novel Antibody Platform Tackles Viral Mutations 2024. Available from: https://www.mountsinai.org/about/newsroom/2024/novel-antibody-platform-tackles-viral-mutations.
 
21 BioSpace. Recent clinical data confirms significantly improved predictive power of Evaxion’s AI-Immunology™ platform 2024. Available from: https://www.biospace.com/press-releases/recent-clinical-data-confirms-significantly-improved-predictive-power-of-evaxions-ai-immunology-platform.
 
22 Biotech F. Celldex’s anti-cKIT antibody proves it can reduce chronic hives in another phase 2 trial 2024. Available from: https://www.fiercebiotech.com/biotech/celldexs-anti-ckit-antibody-again-proves-it-can-reduce-hives-phase-2.
 
23 Arena CT. FDA authorises US trial of Rezolute’s drug candidate for congenital hyperinsulinism 2024. Available from: https://www.clinicaltrialsarena.com/news/fda-hold-rezolute-trial/.
 
24 BioPharmaReporter. Kyverna Therapeutics’ CAR-T cell therapy shows promise against autoimmune diseases 2024. Available from: https://www.biopharma-reporter.com/Article/2024/06/10/kyverna- therapeutics-car-t-cell-therapy-shows-promise-against-autoimmune-diseases.
 
25 Electra Therapeutics Receives FDA Orphan Drug Designation for ELA026 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) 2024. Available from: https://finance.yahoo.com/news/electra-therapeutics- receives-fda-orphan-120000707.html? guce_referrer=aHR0cHM6Ly9kdWNrZHVja2dvLmNvbS8&guce_referrer_sig=A QAAAAF9VdlWbVrABan1jarR0lfqi61Kq9LIo- D1CCANBHWdXgqfvizsYJRdk6BIQ1qE2eJUJuCu37NAqDGDQ
 t6NKJS0IlM22uRkJ EJ7ZIeK4gCPn9GrMhgiLIWXOPXyUzpSF6LmREwlddaHGx_Z43iN0sxgsNrPANq2 38NSKRUbkhDr.
 
26 Astrazeneca. Tezspire (tezepelumab) approved in the US for severe asthma 2021. Available from: https://www.astrazeneca.com/media- centre/press-releases/2021/tezspire-tezepelumab-approved-in-the-us-for-severe-asthma.html#.
 
27 Heo YA. Budesonide/Glycopyrronium/Formoterol: A review in COPD. Drugs. 2021;81(12):1411-22.
https://doi.org/10.1007/s40265-021-01562-6
 
28 Astrazeneca. FASENRA approved for treatment of children aged 6 to 11 with severe asthma 2024. Available from: https://www.astrazeneca- us.com/media/press-releases/2024/fasenra-approved-for-treatment-of- children-aged-6-to-11-with-severe-asthma.html.
 
29 PharmaVoice. Pharma’s immunology field is full of blockbusters, and it’s just getting started 2023. Available from: https://www.pharmavoice.com/news/immunology-Daniel-Cua-Janssen-Merck- Prometheus/648718/.
 
30 Riviere JG, Soler Palacin P, Butte MJ. Proceedings from the inaugural Artificial Intelligence in Primary Immune Deficiencies (AIPID) conference. J Allergy Clin Immunol. 2024;153(3):637-42.
https://doi.org/10.1016/j.jaci.2024.01.002
 
31 Pandya S, Thakur A, Saxena S, Jassal N, Patel C, Modi K, et al. A study of the recent trends of immunology: Key challenges, domains, applications, datasets, and future directions. Sensors (Basel). 2021;21(23):7786.
https://doi.org/10.3390/s21237786
 
32 Stafford IS, Kellermann M, Mossotto E, Beattie RM, MacArthur BD, Ennis S. A systematic review of the applications of artificial intelligence and machine learning in autoimmune diseases. NPJ Digit Med. 2020;3:30.
https://doi.org/10.1038/s41746-020-0229-3

Cite this article as:
Dhar S. Advances in Clinical Immunology. Premier Journal of Immunology 2025;2:100004

Export to EndNote Export to Mendeley